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Abstract
Background: The prevalence of physician-diagnosed-asthma has risen over the past three decades and
misdiagnosis of asthma is potentially common. Objective: to determine whether a secondary-screening-program to
establish a correct diagnosis of asthma in those who report a physician diagnosis of asthma is cost effective.
Method: Randomly selected physician-diagnosed-asthmatic subjects from 8 Canadian cities were studied with an
extensive diagnostic algorithm to rule-in, or rule-out, a correct diagnosis of asthma. Subjects in whom the
diagnosis of asthma was excluded were followed up for 6-months and data on asthma medications and heath
care utilization was obtained. Economic analysis was performed to estimate the incremental lifetime costs
associated with secondary screening of previously diagnosed asthmatic subjects. Analysis was from the perspective
of the Canadian healthcare system and is reported in Canadian dollars.
Results: Of 540 randomly selected patients with physician diagnosed asthma 150 (28%; 95%CI 19-37%) did not
have asthma when objectively studied. 71% of these misdiagnosed patients were on some asthma medications.
Incorporating the incremental cost of secondary-screening for the diagnosis of asthma, we found that the average
cost savings per 100 individuals screened was $35,141 (95%CI $4,588-$69,278).
Conclusion: Cost savings primarily resulted from lifetime costs of medication use averted in those who had been
misdiagnosed.
Keywords: Asthma cost Canadian asthma cost, asthma cost savings, asthma secondary screening, economic analy-
sis, epidemiology of asthma
Background
Over the past 3 decades the prevalence of physician-diag-
nosed asthma has increased more than 75% in Canada and
in the US [1,2]. Studies from Canada suggest that less than
50% of Canadians receive lung function testing before a
diagnosis of asthma is assigned by their physician [3,4].
Therefore for most Canadians a diagnosis of asthma is
usually made on clinical grounds alone [3,4]. Similarly,
underuse of spirometry in the US [5] and Europe [6] in
establishing the diagnosis of asthma is well known.
A recent study [7] by our group determined the pro-
portion of obese and normal weight Canadian adults
with an incorrect diagnosis of asthma. Subjects were ran-
domly sampled from 8 cities across Canada by random
digit dialing. Subjects were included in the study if they
were at least 16 years old, if they were obese (BMI ≥ 30)
or normal weight (BMI 20-25), and if they identified
themselves as having current, physician-diagnosed
asthma. Details of the study design, subject selection, and
the diagnostic algorithm for establishing the diagnosis of
asthma are discussed elsewhere [7]. This study showed
that approximately 30% of enrolled subjects with a his-
tory of physician-diagnosed asthma did not have asthma
after they were objectively assessed with lung function
and bronchial challenge testing and after their asthma
medications were tapered off. Misdiagnosis rates were
similar in both obese and non-obese subjects.
Adult patients who receive a lifetime diagnosis of a
c h r o n i cd i s e a s el i k ea s t h m ae x p e r i e n c ef r e q u e n ta c t i v i t y
limitation and potential psychological distress [8]. A diag-
nosis of asthma can mean a personal and economic burden
for patients. Recently, a study from the USA showed that
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asthma in adults was $2077. Prescription medication and
physician office visits were the major drivers of this cost,
accounting for 38% and 49% of the cost respectively [9].
A detailed analysis of asthma costs in Canada showed that
the total cost of asthma in 1990 Canadian dollars was esti-
mated to be $504 to $648 million. The single largest com-
ponent of direct costs was the cost of drugs ($124 million)
[10].
Overdiagnosis of asthma in the general population is
an important public health concern. Mislabeling subjects
with a chronic illness like asthma could cost health care
dollars and also could adversely affect health related
quality of life. In addition, a misdiagnosis of asthma may
mean that the actual undiagnosed underlying illness
remains untreated. Non-treatment or under-treatment
of the patient’s actual illness could lead to potentially
preventable long term complications which might
further jeopardize the health status of the patient and
further increase costs.
Our study on asthma misdiagnosis included a concur-
rent prospective economic analysis. Data on resource
use were prospectively collected during the study and
analysis of these data is presented here. The specific
objective of the present study was to determine, using
cost-effectiveness analyses, whether a diagnostic strategy
to confirm asthma in patients with physician-diagnosed
asthma was cost-effective.
Methods
The present cost-effectiveness analysis is based upon data
from the asthma misdiagnosis longitudinal study invol-
ving normal weight and obese physician-diagnosed asth-
matic subjects [7]. In this study, individuals who reported
a physician diagnosis of current asthma were randomly
selected from eight metropolitan areas of Canada
through random-digit dialing. Subjects with > 10 pack
year history of smoking were excluded in order to
prevent enrollment of patients with chronic obstructive
pulmonary disease (COPD). The individuals then under-
went a series of lung function tests and a diagnosis of
current asthma was excluded in those who did not have
evidence of acute worsening of asthma symptoms, rever-
sible airflow obstruction or bronchial hyperresponsive-
ness, despite being weaned off asthma medications.
Asthma medications were stopped in those in whom a
diagnosis of asthma was excluded and their clinical out-
comes were assessed over a 6 month period prospec-
tively. Further details of the study design, subject
recruitment, and methods are described elsewhere [7].
The asthma diagnostic algorithm used in the study [7] is
presented in figure 1. The study was approved by the
research ethics boards of the 8 participating study hospi-
tals; economic analysis was part of the ethics application.
All patients who participated in the study gave written
informed consent.
This analysis focuses on estimating the incremental
lifetime costs associated with screening previously diag-
nosed asthmatic subjects. Analysis was from the perspec-
tive of the Canadian healthcare system and subjects were
presumed to live a maximum of 50 years from the time
of first diagnosis of asthma (although this was varied to
25 years for sensitivity analysis). Costs included the costs
of the diagnostic testing algorithm and the lifetime costs
of any medication use averted due to misdiagnosis.
Costs
Healthcare resource use prior to diagnostic screening, dur-
ing screening and up to six months post screening was
collected prospectively for each patient according to the
s t u d yp r o t o c o l .T h ep r i n c i p a lresource items of interest
were the costs of asthma medications, costs of testing to
confirm diagnosis of asthma, costs of emergency room
visits, and the cost of a respiratory disease specialist con-
sultation. In a sensitivity analysis, we explored the impact
on cost savings if the screening diagnostic algorithm could
be managed by a general practitioner rather than by a spe-
cialist. The prices of all medications were based on listed
prices in the Ontario Drug Benefit Formulary plus the
pharmacy markup and dispensing fee
8. All medications
were recorded by drug name, dose, route, frequency and
duration, enabling an accurate calculation of costs for
each patient. The cost of physician visits and emergency
department visits was based on the Ontario Ministry of
Health [11,12]. The costs of spirometry testing, bronchial
provocative testing and specialist and general practitioner
consultation were based on the Ontario Schedule of Bene-
fits 2009 [13]. All costs are presented in 2009 Canadian
dollars (tables 1 and 2). The cost of spirometry testing and
bronchial provocation testing includes laboratory fee, tech-
nician fee, and respiratory specialists’ interpretation fee.
Determination of Incremental Costs of The Diagnostic
Screening Algorithm
Based on the results of the diagnostic screening, indivi-
duals in the longitudinal study were categorized into
three groups: those determined not to be asthmatic,
those that had their diagnosis of asthma confirmed, and
others (individuals who withdrew before all test were
completed and who could not be classified as having
asthma or not). For the latter two categories we
assumed that diagnostic screening will not affect the
future costs associated with asthma. Thus, the incre-
mental costs were solely the costs of the diagnostic
screening itself for these two categories.
Those determined not to be asthmatic were followed
up prospectively for six months after the conclusion of
the diagnostic screening. Resource use that could be
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Page 2 of 9associated with asthma care was monitored and was
considered an incremental cost associated with the diag-
nostic screening. For those in whom asthma was ruled
out by our diagnostic algorithm, and who were on medi-
cation prior to diagnostic screening we estimated the
lifetime costs of medication use avoided as a result of
the diagnostic screening. This required a four step
approach. First, from the longitudinal study we esti-
mated the probability that non asthmatics would be on
medication in the year after the diagnosis of asthma
Visit 1
Pre- and Post-bronchodilator spirometry
Visit 2
Bronchial challenge test with methacholine
Visit 3
Bronchial challenge test with methacholine
Visit 4
Bronchial challenge test with methacholine
Asthma confirmed
PC20  8 mg/mL
FEV1 does not increase by
 200 mL and  15%
Dose of inhaled corticosteroids halved and 
leukotriene antagonists discontinued; 
retesting in 2-3 weeks
Inhaled corticosteroids and 
long-acting bronchodilators discontinued; 
retesting in 2-3 weeks
FEV1 increases
by  200 mL
and  15%
Asthma confirmed
Asthma confirmed
Asthma confirmed
Asthma excluded
Asthma medications stopped 
and patient followed up for 6 mo.
PC20  8 mg/mL
PC20 >8  m g / m L
PC20  8 mg/mL
PC20 >8  m g / m L
PC20 >8  m g / m L
Figure 1 Serial asthma testing algorithm (Confirmed Asthma = 346, Asthma excluded = 150) (PC20 - the provocation concentration
that caused decrease in forced expiratory volume in 1 second (FEV1) of 20%).
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Page 3 of 9Table 1 Unit costs (2009 CAN$) for each drug as per the Ontario Drug Benefit Formulary/Comparative Index
Drug Name Formulation Cost per puff or pill
1. Short Acting Beta-agonist
Salbutamol (Ventolin) 100 mcg MDI, 200 dose pk $0.08
2. Long Acting Beta-agonist (LABA)
Salmeterol (Serevent) Diskus 50 mch Pd Inh-60 Dose Pk $1.10
3. Inhaled Steroids (ICS)
Fluticasone (Flovent) 250 mcg MDI Inh-120 Dose Pk $0.78
4. Cromolyn
Nedocromil sodium (Tilade) Puffer, 104 dose Pk $0.42
5. Leukotriene Antagonist
Montelukast (Singulair) 10 mg pill, 30 pills $3.21
6. Combination 1 (ICS/LABA)
Budesonide/Formeterol (Symbicort) 200 mcg/6 mcg Pd Inh-120 Dose Pk $0.76
Fluticasone/Salmeterol (Advair) Diskus 50/250 mcg Inh-60 Dose Pk $1.80
7. Combination 2
Salbutamol/ipratropium bromide(Combivent) 20 mcg/100 mcg/md Aero 200 Dose Pk $0.15
8. Prednisone 50 mg tab, 30 pills $0.33
9. Tiopropium bromide (Spiriva) 18 mcg Cap, 30 pills $2.50
Table 2 Healthcare and Testing costs for all individuals and asthma medications for individuals for whom the
diagnosis of asthma was excluded
Item Costs per visit/test Reference
Physician consultations Ontario Schedule of Benefits 2008
Respiratory disease consult $143.40
GP Limited consultation $44.65
Emergency Department Assessment $187.76 Ontario Ministry of Health: Gaboury 2009
Spirometry B (Visit 1) Ontario Schedule of Benefits 2008
Flow Volume Loop $28.80
Repeat after bronchodilator $8.63
Total $37.43
Bronchial provocative testing (Visits 2, 3 and 4) $80.45 Ontario Schedule of Benefits 2008
Total Cost of Screening
Visit 1 only (11.2%) $180.83*
Visits 1 and 2 only (80.2%) $261.28*
Visits 1, 2 and 3 only (3.3%) $341.73*
All Visits (5.3%) $422.18*
Average cost of Screening for all patients $263.42 (95%CI $259.15 - $267.68)
Average cost of Screening for Non-Asthmatic patients $288.10 (95%CI $278.94 - $297.25)
Study Medication Number of individuals (%)
SABA** as needed only 26 (23.9%)
SABA daily only 1 (0.9%)
ICS
# as needed only 3 (2.8%)
ICS daily only 1 (0.9%)
ICS as needed plus SABA 23 (21.1%)
ICS daily plus SABA 12 (11.0%)
COMBO
## as needed only 6 (5.5%)
COMBO as needed plus other medications 13 (11.9%)
COMBO daily only 2 (1.8%)
COMBO daily plus other medications 17 (15.6%)
Leukotriene Antagonist (all combinations) 5 (4.6%)
* Includes the costs of a respiratory disease specialist consultation.
** SABA - Short-acting b-agonist.
# ICS - Inhaled corticosteroids.
## COMBO - combination therapy with ICS and long-acting b-agonist.
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(figure 2). For the 20 individuals (3.7%) for whom infor-
mation on the year of diagnosis was missing we used
the average years since diagnosis for each group. Sec-
ondly, we estimated the cost of medication by year since
diagnosis for those in whom asthma was ruled out. This
was estimated through linear regression analysis using
data from the longitudinal study to adjust for increase
in costs of annual medication based on year of diagno-
sis. Thirdly, we estimated the discounted lifetime cost
associated with asthmatic medication for subjects in
whom the diagnosis of asthma was ruled out by our
diagnostic algorithm (figure 3). The discounted lifetime
cost was the product of the probability of being on med-
ication, the cost of medication and the discount factor,
for each subsequent year. Finally we allocated the life-
time cost of medication based on the specific year since
diagnosis for each subject who had been taking asthma
medication, in whom the diagnosis of asthma was even-
tually ruled out by our testing algorithm.
Statistical Analysis
Outcome is presented as the incremental costs of
screening per 100 subjects screened. Uncertainty around
these estimates were obtained through non-parametric
bootstrapping whereby numerous estimates of outcomes
is obtained by sampling with replacement from the ori-
ginal data set to obtain a new data set of the same size.
These bootstrap estimates are assumed to provide
empirical distribution of the data which is an adequate
representation of the true distribution of the data.
Uncertainty is thus represented by the set of estimates
obtained from the observed data [14]. A random sample
of 100 individuals from the original data from each
group was bootstrapped. For each iteration of bootstrap-
ping (n = 5000), we calculated the percentage of indivi-
duals who were not asthmatic, percentage of non
asthmatic individuals who were on medication and the
incremental cost of screening. These outcomes were
then averaged over the 5000 bootstrap replicates; means
and 95% Credible Intervals (CI) were calculated. Sensi-
tivity analysis was conducted on drugs that were taken
as needed (e.g. short-acting bronchodilators); the first
approach was to use a low number of inhalations per
week (1 to 2 inhalations per week) and the second
approach was to use a high number of inhalations per
week (4 to 8 inhalations per week). All analyses were
conducted using SPSS 16.0.
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Figure 2 Years since diagnosis of asthma and probability of being on asthma medication.
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Asthma diagnosis and medications
Five-hundred and forty individuals with physician-diag-
nosed asthma entered into the study, however 41 patients
withdrew prematurely before study completion and three
patients were categorized as ‘unable to classify’ because
their baseline FEV1 was less than 60% predicted and they
were unable to safely undergo a bronchial challenge test.
In total 496 individuals completed all of the study assess-
ments and could be conclusively evaluated for a diagnosis
of asthma. Of the 496 patients who could be conclusively
diagnosed, 346 were confirmed to have asthma and 150
did not have asthma when objectively studied. We were
thus able to exclude a diagnosis of asthma in 150 of the
540 subjects who entered into the study (28%; 95% CI:
19-37%). Of these, 109 (73%) were currently taking
asthma medications - 37 of these on a daily basis.
The number of years since diagnosis of asthma and
probability of being on asthma medication in the cohort of
subjects in whom diagnosis of asthma was ruled out is
depicted in figure 2. Although the majority of patients
began using daily asthma medication at the point of initial
diagnosis, less than 50% were on daily medication ten
years after their diagnosis date. However, more than half
were still on some form of asthma medication on an inter-
mittent basis, even 30 years after diagnosis.
Linear regression analysis was employed to adjust for
any increase in the costs of annual medication based on
years since diagnosis. We incorporated the increasing
annual costs of medication each year (an increase of
$1.67 (95% CI: -$6.10 to $9.45) although this increase
was small and was not statistically significant. Accumu-
lated costs of asthma medications increased with length
of time since diagnosis. Ten years after diagnosis, the
discounted accumulated cost of asthma medication was
approximately $2000 (Figure 3).
Table 2 shows the cost of screening patients for
asthma. The cost of physiological testing at each step of
the screening algorithm (figure 1) was $37.43 for the first
step and $80.45 for steps 2, 3 and 4. In addition, we
assumed each participant would have one respiratory dis-
ease specialist consultation (an additional cost of
$143.40). Thus, if a patient underwent all the steps in the
screening algorithm, the total cost per patient would be
$0
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Figure 3 Discounted lifetime cost of asthma medication by years since diagnosis for the subjects where diagnosis of asthma was
ruled out by diagnostic algorithm.
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Page 6 of 9$422.18 (Table 2). However, 91.4% of patients required
only two or fewer steps of the screening algorithm [15].
Thus, the average cost per patient of the asthma screen-
ing algorithm was $263.42 for all patients and $288.10
for those for whom a diagnosis of asthma was excluded.
Table 2 also provides the breakdown in asthma medica-
tion by individuals for whom a diagnosis of asthma was
excluded - this represents the resources that can be saved
through exclusion of asthma diagnosis.
Economic Impact of Screening
On average, 28% (95% CI: 19-37%) of subjects did not
have asthma (Table 3). Of these, 71.4% (95% CI: 46.4-
100%) were on some asthma medications. Incorporating
the incremental cost of screening for the diagnosis of
asthma and the forecasted cost savings through identifi-
cation of patients who were not asthmatics, we found
that the average cost savings per 100 individuals screened
was $35,141 (95% CI: $4,588 to $69,278) (Table 3).
Sensitivity analysis
Three sensitivity analyses were conducted (Table 3).
First, analysis restricted the time horizon to only 25
years. Based on this assumption the average cost savings
per 100 individuals screened were reduced: $24,390
(95% CI: $1,181 to $47,600)
Secondly, analysis explored the incremental cost sav-
ings if the screening could be undertaken assuming only
a GP consultation rather than a specialist consultation.
Based on this assumption the average cost savings per
100 individuals screened increased to $45,016 (95% CI:
$14,463 to $79,153)
Finally, a sensitivity analysis was conducted on drugs
that were taken as needed, for a low number of inhala-
tions per week (1 to 2 puffs of as needed inhaled short-
acting bronchodilator medication per week) the average
cost savings per 100 individuals screened was $29,798
(95%CI: -$3,396 to $102,307) and for a high number of
inhalations per week (4 to 8 puffs per week) the average
Table 3 Results of non-parametric bootstrapping and sensitivity analysis
Characteristics Per 100 Patients screened
% Not Asthmatic 28
2.5% Credible Interval 19
97.5% Credible Interval 37
% Not Asthmatic and on Daily Medication 20
2.5% Credible Interval 13
97.5% Credible Interval 28
Average Cost Savings $35,141
2.5% Credible Interval $4,588
97.5% Credible Interval $69,278
*Average cost saving per patient screened is $ 351
Sensitivity Analysis
25 year time horizon
Average Cost Savings $24,390
2.5% Credible Interval $1,181
97.5% Credible Interval $47,600
*Average cost saving per patient screened is $ 243
GP consult rather than specialist
Average Cost Savings $45,016
2.5% Credible Interval $14,463
97.5% Credible Interval $79,153
*Average cost saving per patient screened is $ 450
As needed 1 to 2 puffs of short-acting bronchodilator per week
Average Cost Savings $29,798
2.5% Credible Interval -$3,396
97.5% Credible Interval $102,307
*Average cost saving per patient screened is $ 298
As needed 4 to 8 puffs of short-acting bronchodilator per week
Average Cost Savings $41,606
2.5% Credible Interval $474
97.5% Credible Interval $113,843
*Average cost saving per patient screened is $ 416
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Page 7 of 9cost savings per 100 individuals screened was $41,606
(95% CI: -$474 to -$113,843).
Discussion
This economic analysis of our large multi-center longi-
tudinal study sheds light on the long term economic
implications of asthma misdiagnosis. We discounted the
impacts of substantial cost savings accumulating over
time within the analysis to reflect societal preferences
for the timing of events. However, even after discount-
ing we found a significant cost associated with asthma
misdiagnosis. Lifetime costs for asthma medications in
misdiagnosed patients (who would not be expected to
benefit from these medications since they did not have
asthma) amounted to over $4000 per patient.
We undertook our study to objectively screen ran-
domly-selected individuals with a previous physician
diagnosis of asthma in order to confirm asthma in these
individuals. The average cost savings per patient screened
was more than $351. In Canada which has a population
> 33 million, the prevalence of physician-diagnosed
asthma is 8.5%, and more than 2.8 million people have
been diagnosed with asthma. If one assumes an asthma
misdiagnosis rate of 28-30% then this would imply that
over 785,000 people have been mistakenly diagnosed. A
secondary screening program to conclusively establish a
diagnosis of asthma in those who have been previously
diagnosed, such as described in this study, would be
expected to remove many mistaken diagnoses and could
ultimately generate more than $275 million in cost sav-
ings. The saved health care dollars could be redirected to
better manage asthma in those who are truly confirmed
to have the condition [13]. Though our study is based
upon Canadian data, asthma diagnostic practices are
quite similar throughout North America [5] or Europe
[6]. However the costs of asthma medications in the US
are considerably higher than in Canada [16,17].
The major strength of this analysis is that all the drug
costs are based on accurate data prospectively collected
from subjects rather than estimates. The non-parametric
bootstrapping used in this analysis enabled full incor-
poration of the uncertainty arising from the limited
sample size.
Cost analysis is an inexact science; and there are built-
in limitations to cost-analysis studies. Measurement
errors, uncertainties in the estimates, and recall bias
may affect data obtained from such studies - although
the direction of such bias is unknown. We have
attempted to account for some of these limitations by
considering most conservative estimates of costs and by
obtaining cost information from multiple sources. In
a d d i t i o n ,b e c a u s ew ed i dn o th a v ed a t at od e t e r m i n e
indirect costs; we only analyzed direct healthcare costs
in this study.
A systematic analysis recently summarized the eco-
nomic burden of asthma in developed and some devel-
oping countries [18]. Most of these studies are based
upon databases [17,19], cross-sectional survey data [10],
patient re-call [16,19,20] or estimation of costs [10,17].
All these studies included direct and indirect costs of
asthma which included costs of asthma management,
asthma medications, asthma related urgent care utiliza-
tion and absenteeism related cost [21]. None of these
studies addressed the issue of asthma misdiagnosis or
the costs associated with diagnosing or misdiagnosing
asthma.
Establishing a correct diagnosis of asthma even in sub-
jects diagnosed many years ago seems to be a cost effec-
tive option. Whether this should be done via a
widespread secondary screening program based upon
the algorithm utilized in our study or whether it should
be done on a case-by-case basis is open to discussion.
Organized, secondary screening programs could be a
viable option as shown by our study. Our secondary
screening program is not onerous for patients; over 91%
of patients seen in our study required only a single pre
and post bronchodilator spirometry and/or a single
bronchial challenge test to confirm asthma [15]. In the
long run, such an approach is cost effective considering
the direct and indirect costs associated with misdiagno-
sis. Merely labeling subjects with chronic illness has its
toll, as was shown by increased absenteeism in subjects
who were made aware of their diagnosis of hypertension
even when they were not started on any antihyperten-
sive medication [22].
A potential limitation of our study is that our algo-
rithm does not incorporate costs associated with estab-
lishing alternative diagnoses in those patients in whom
asthma was ruled out. Our costing algorithm already
incorporates a consultation with a respiratory medicine
specialist, so the physician cost of making alternative
d i a g n o s e si sa c c o u n t e df o r .H o w e v e ri ti sp o s s i b l et h a t
once a diagnosis of asthma is excluded, additional test-
ing to confirm alternative diagnoses other than asthma
might or might not be required. If this testing occurs,
these costs would not be attributable to our algorithm
which is designed to rule in or rule out asthma, and not
other diseases. Further research is needed to estimate
follow-up costs to establish an alternative diagnosis,
once the diagnosis of asthma is ruled out.
Our study adopted a 50 year time horizon to measure
the cost savings from the reduction in medication. This
does not assume that all patients will live a further 50
years - rather it accumulates the cost savings from the
point of screening up until death or 50 years whichever
comes first. Adopting a lifetime horizon is standard
practice in economic evaluations of chronic diseases.
However, there is concern that extrapolation for such a
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the shorter the time horizon adopted in our analysis the
less the accumulated cost savings. Sensitivity analysis
adopting a 25 year time horizon still found significant
cost savings providing confidence to our results.
Conclusion
In summary, we have shown that making a proper
diagnosis of asthma is cost effective and cost saving.
We performed diagnostic tests on those who had
already been diagnosed with asthma in the past.
Though we do not know how the diagnosis of asthma
was made initially, we have shown that confirming a
proper diagnosis of asthma with physiological tests is
cost saving since many patients who are found to have
been misdiagnosed can be safely discontinued from
their asthma medications. In order to avoid the direct
medication costs and the indirect cost of carrying a
wrong diagnosis of a chronic disease such as asthma,
family physicians and specialists need to be encouraged
to obtain physiological tests such as spirometry and
bronchial challenge tests to correctly diagnose and
confirm asthma.
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